RTP Mobile Logo
Submitted by nenadkesic@gmail.com on Wed, 11/15/2017 - 06:54
ONUL117

Interview with Amy Goodrich, CRNP-AC

Track 1 Case: A 66-year-old man who received multiple lines of therapy for chronic lymphocytic leukemia (CLL) without undergoing mutational testing is ultimately determined to harbor a 17p deletion
Track 2 Clinical experience with venetoclax in CLL
Track 3 Monitoring for and preemptive measures to address the risk of tumor lysis syndrome in patients with CLL about to initiate therapy with venetoclax
Track 4 Identification and management of idelalisib-related colitis
Track 5 Evolving role of obinutuzumab based on the results of the Phase III GALLIUM study of obinutuzumab- versus rituximab-based induction and maintenance therapy for patients with previously untreated follicular lymphoma
Track 6 Frequency and severity of obinutuzumab-associated infusion-related reactions
Track 7 Subcutaneous versus intravenous administration of rituximab
Track 8 Case: A 67-year-old man with relapsed mantle cell lymphoma (MCL) who received the “R-squared” regimen of lenalidomide/rituximab
Track 9 Evolving treatment landscape for older and younger patients with MCL
Track 10 Counseling patients who are about to begin treatment with lenalidomide
Track 11 Case: A 74-year-old man with Stage IV peripheral T-cell lymphoma (PTCL) with widespread adenopathy and bone involvement
Track 12 Choosing among available treatment options for relapsed PTCL: pralatrexate, romidepsin and belinostat
Track 13 Significance of establishing short-term personal goals in patients living with incurable cancer
Track 14 Finding meaning and satisfaction as an oncology nurse

Interview with John P Leonard, MD

Track 1 Counseling patients with lymphoma about disease classification and goals of treatment
Track 2 Factors influencing the development of lymphoma and effect of lymphoma subtype on long-term prognosis
Track 3 Case: A 77-year-old man is observed for several years before receiving multiple lines of treatment for CLL
Track 4 Selection of an up-front treatment regimen for patients requiring active therapy for CLL
Track 5 Later-line options for the treatment of CLL; prognostic and therapeutic significance of 17p deletion
Track 6 Tolerability profile of the Bruton tyrosine kinase inhibitor ibrutinib
Track 7 Explaining the mechanism of action of ibrutinib to patients with CLL and other lymphomas
Track 8 Mechanism of action and side-effect profile of venetoclax in CLL
Track 9 Monitoring and treatment strategies for tumor lysis syndrome in patients receiving venetoclax
Track 10 Role of maintenance therapy in CLL
Track 11 Rationale for combining lenalidomide with rituximab and ongoing evaluation of this regimen in different lymphoma subtypes

Interview with Jonathan L Kaufman, MD

Track 1 Case: A 75-year-old man with relapsed multiple myeloma (MM) who initially presented with severe back pain is found on evaluation to have renal insufficiency and compression fractures
Track 2 Pathophysiology of renal dysfunction in patients with MM
Track 3 Approach to induction therapy for patients with MM with and without renal insufficiency
Track 4 Carfilzomib as a component of front-line therapy for patients with MM
Track 5 Clinical experience with carfilzomib-associated dyspnea and cardiac dysfunction
Track 6 Minimal residual disease detection in MM
Track 7 Trials investigating the role of transplant in the era of effective up-front treatment strategies for MM
Track 8 Benefit of indefinite lenalidomide maintenance after autologous stem cell transplant (ASCT)
Track 9 Management of toxicities such as diarrhea and rash associated with maintenance lenalidomide
Track 10 Use of bortezomib maintenance in a patient who did not receive lenalidomide as part of induction therapy for MM
Track 11 Combination strategies for the treatment of MM in first relapse: elotuzumab/ lenalidomide/dexamethasone, carfilzomib/lenalidomide/dexamethasone and ixazomib/lenalidomide/dexamethasone
Track 12 Clinical experience with ixazomib and potential advantages to the use of an oral agent in the maintenance setting
Track 13 Activity and tolerability of daratumumab-based regimens for relapsed/refractory (R/R) MM
Track 14 Rationale for the investigation of pomalidomide in combination with other agents for patients with R/R MM
Track 15 Safety and efficacy of venetoclax monotherapy in R/R MM

Interview with Kevin Brigle, PhD, ANP

Track 1 Case: A 47-year-old woman with newly diagnosed MM receives lenalidomide/ bortezomib/dexamethasone (RVD) induction followed by transplant and lenalidomide maintenance
Track 2 Educating patients about the goals of treatment and expectations surrounding ASCT
Track 3 Dosing and tolerability considerations in patients with MM receiving indefinite lenalidomide maintenance therapy
Track 4 Practical considerations with the use of carfilzomib
Track 5 Case: An 88-year-old woman presents with worsening neuropathy and is found to have elevated M protein in the serum and a bone marrow biopsy showing 20% plasma cells
Track 6 Choice of an induction regimen in older patients with MM
Track 7 Risk of second primary cancer in patients receiving lenalidomide maintenance therapy
Track 8 Case: A 65-year-old man receives multiple lines of therapy for R/R MM, including most recently daratumumab with pomalidomide
Track 9 Efficacy and tolerability of daratumumab and elotuzumab for R/R disease
Track 10 Case: A 66-year-old woman with MM experiences disease progression while receiving lenalidomide maintenance and is switched to the all-oral regimen of ixazomib/lenalidomide/dexamethasone
Track 11 Factors affecting a patient’s ability to cope with the diagnosis and treatment of cancer
 
FACULTY:
 
Amy Goodrich, CRNP-AC
Nurse Practitioner
Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland
 
John P Leonard, MD
Richard T Silver
Distinguished Professor of
Hematology and Medical Oncology
Associate Dean for Clinical Research
Weill Cornell Medical College
New York, New York
 
Jonathan L Kaufman, MD
Associate Professor of
Hematology and Medical Oncology
Winship Cancer Institute of
Emory University
Atlanta, Georgia
 
Kevin Brigle, PhD, ANP
VCU Massey Cancer Center
Richmond, Virginia
 
EDITOR:
Neil Love, MD
Research To Practice
Miami, Florida